Moderna (MRNA) shares are paring back some of their recent gains on Thursday morning – but a Morgan Stanley analyst believes Merck MRK stock remains a buy following blockbuster cancer drug trial …
Moderna is paring back gains, but Merck stock remains a buy
view original post